State Street’s Revelation Biosciences REVB Stock Holding History

State Street’s Portfolio REVB Stock Details REVB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-1	Closed	-$20.9K	–	4817
2022 Q4	$20.9K	Hold	1	–	–	﹤0.01%	4726
2022 Q3	$28K	Buy	+1	New	+$120K	﹤0.01%	4779

Other funds holding REVB

AFM

Anson Funds Management Dallas, Texas $2.29B AUM 370.24% 1-Year Est. Return

Sabby Management Miami Beach, Florida $45.1M AUM 74.25% 1-Year Est. Return

Walleye Capital New York $24B AUM 37.67% 1-Year Est. Return

Hudson Bay Capital Management Stamford, Connecticut $29B AUM 30.2% 1-Year Est. Return

Axa Paris, France $256M AUM 25.01% 1-Year Est. Return

ACM

Altium Capital Management New York $42M AUM

CVI Holdings Wilmington, Delaware $116M AUM 5.68% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

State Street's REVB Position: Q1 2023 in Review

State Street sold out of Revelation Biosciences (REVB) in Q1 2023, closing a stake of 1 share — an estimated $20.9K sold.

State Street first reported a position in REVB in Q3 2022 and held it in 2 quarters. The position peaked at $28K in Q3 2022. 7 funds tracked by Wall St. Rank hold REVB as of Q1 2023.

State Street reported no remaining Revelation Biosciences position as of Q1 2023 after selling out during the quarter.
State Street sold 1 Revelation Biosciences share in Q1 2023, an estimated $20.9K.
State Street first reported a position in Revelation Biosciences in Q3 2022 and held it in 2 quarters.
State Street's Revelation Biosciences position peaked at $28K in Q3 2022.
7 funds tracked by Wall St. Rank held Revelation Biosciences as of Q1 2023.

Based on State Street's 13F filing for Q1 2023, filed 15 May 2023.